LAM
REGN icon

LECAP Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

LECAP Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-816
Closed -$630K – 360
2026
Q1 		$630K Buy
816
+467
+134% +$358K 0.24% 168
2025
Q4 		$269K Sell
349
-68
-16% -$46.2K 0.11% 251
2025
Q3 		$234K Buy
+417
New +$236K 0.08% 258
2025
Q1 		– Sell
-1,243
Closed -$885K – 378
2024
Q4 		$885K Buy
1,243
+262
+27% +$220K 0.24% 158
2024
Q3 		$1.03M Buy
+981
New +$1.09M 0.22% 160
2024
Q2 		– Sell
-743
Closed -$715K – 400
2024
Q1 		$715K Buy
743
+464
+166% +$441K 0.15% 227
2023
Q4 		$245K Buy
+279
New +$230K 0.09% 269

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

LECAP Asset Management's REGN Position: Q2 2026 in Review

LECAP Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 816 shares — an estimated $630K sold.

LECAP Asset Management first reported a position in REGN in Q4 2023 and held it in 7 quarters. The position peaked at $1.03M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • LECAP Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LECAP Asset Management sold 816 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $630K.
  • LECAP Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • LECAP Asset Management's Regeneron Pharmaceuticals position peaked at $1.03M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on LECAP Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.